• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rivaroxaban versus warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation: A meta-analysis.

作者信息

Phan Kevin, Wang Nelson, Pison Laurent, Kumar Narendra, Hitos Kerry, Thomas Stuart P

机构信息

Department of Cardiology, Westmead Hospital, Sydney, Australia.

University of Sydney, Sydney, Australia.

出版信息

Int J Cardiol. 2015 Apr 15;185:209-13. doi: 10.1016/j.ijcard.2015.03.102. Epub 2015 Mar 10.

DOI:10.1016/j.ijcard.2015.03.102
PMID:25797679
Abstract
摘要

相似文献

1
Rivaroxaban versus warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation: A meta-analysis.利伐沙班与华法林或达比加群用于房颤导管消融患者的比较：一项荟萃分析。
Int J Cardiol. 2015 Apr 15;185:209-13. doi: 10.1016/j.ijcard.2015.03.102. Epub 2015 Mar 10.
2
Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.达比加群或利伐沙班与维生素K拮抗剂新治疗的非瓣膜性心房颤动患者出血和动脉血栓栓塞事件短期风险的比较：一项法国全国性倾向匹配队列研究。
Circulation. 2015 Sep 29;132(13):1252-60. doi: 10.1161/CIRCULATIONAHA.115.015710. Epub 2015 Jul 21.
3
Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation.比较利伐沙班与华法林或达比加群在接受导管消融治疗心房颤动患者中的疗效和安全性的荟萃分析。
Am J Cardiol. 2014 Aug 15;114(4):577-82. doi: 10.1016/j.amjcard.2014.05.038. Epub 2014 Jun 6.
4
Periprocedural Management of New Oral Anticoagulants in Atrial Fibrillation Ablation.心房颤动消融术中新型口服抗凝剂的围手术期管理
J Cardiovasc Pharmacol Ther. 2015 Sep;20(5):457-64. doi: 10.1177/1074248415576193. Epub 2015 Mar 31.
5
Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation.亚洲非瓣膜性心房颤动患者使用利伐沙班和达比加群的血栓栓塞、出血和死亡率风险。
J Am Coll Cardiol. 2016 Sep 27;68(13):1389-1401. doi: 10.1016/j.jacc.2016.06.062.
6
Safety of dabigatran or rivaroxaban for thoracoscopic ablation in patients with atrial fibrillation.达比加群或利伐沙班用于房颤患者胸腔镜消融术的安全性。
Int J Cardiol. 2015;186:213-5. doi: 10.1016/j.ijcard.2015.03.229. Epub 2015 Mar 18.
7
Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation.新型口服抗凝药用于心房颤动消融患者的安全性
J Interv Card Electrophysiol. 2014 Jun;40(1):33-8. doi: 10.1007/s10840-014-9888-9. Epub 2014 Mar 19.
8
Efficacy and safety of rivaroxaban compared with vitamin K antagonists for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis.利伐沙班与维生素K拮抗剂用于心房颤动导管消融围手术期抗凝的疗效和安全性：一项系统评价和荟萃分析。
Europace. 2016 Dec;18(12):1787-1794. doi: 10.1093/europace/euv408. Epub 2016 Jan 20.
9
Rivaroxaban in atrial fibrillation cardioversion: insights from the X-VeRT trial.利伐沙班用于心房颤动复律：来自X-VeRT试验的见解。
Future Cardiol. 2015 Mar;11(2):147-51. doi: 10.2217/fca.15.4.
10
[Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation].[非瓣膜性心房颤动患者中直接口服抗凝剂与维生素K拮抗剂相关因素]
Therapie. 2015 Nov-Dec;70(6):485-92. doi: 10.2515/therapie/2015032. Epub 2015 Jul 29.

引用本文的文献

1
UBLED AF (Uninterrupted BLackpool EDoxaban vs Warfarin vs Rivaroxaban in Atrial Fibrillation/Flutter ablation) Study.UBLED AF（房颤/房扑消融术中不间断使用拜瑞妥与华法林及利伐沙班对比）研究
J Atr Fibrillation. 2021 Aug 31;14(2):20200445. doi: 10.4022/jafib.20200445. eCollection 2021 Aug.
2
Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.房颤导管消融患者中依度沙班与维生素K拮抗剂的持续给药：ELIMINATE-AF研究的原理与设计
Clin Cardiol. 2018 Apr;41(4):440-449. doi: 10.1002/clc.22918. Epub 2018 Apr 17.
3
Periprocedural Management of Direct Oral Anticoagulants Surrounding Cardioversion and Invasive Electrophysiological Procedures.
心脏复律和侵入性电生理手术前后直接口服抗凝剂的围手术期管理。
Cardiol Rev. 2018 Sep/Oct;26(5):245-254. doi: 10.1097/CRD.0000000000000188.
4
Periprocedural Anticoagulation Management for Atrial Fibrillation Ablation: Current Knowledge and Future Directions.心房颤动消融围手术期抗凝管理：当前认知与未来方向
Curr Treat Options Cardiovasc Med. 2018 Jan 25;20(1):3. doi: 10.1007/s11936-018-0600-8.
5
2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation.2017年心房颤动导管消融与外科消融治疗专家共识声明（由心律学会、欧洲心律协会、欧洲心血管病预防与康复协会、亚太心律学会、拉丁美洲心脏节律学会联合发布）
Europace. 2018 Jan 1;20(1):e1-e160. doi: 10.1093/europace/eux274.
6
2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation.2017年心房颤动导管消融与外科消融治疗专家共识声明：由心律学会（HRS）、欧洲心律协会（EHRA）、欧洲心血管病预防与康复协会（ECAS）、亚太心律学会（APHRS）及拉丁美洲心脏学会（SOLAECE）联合发布
Heart Rhythm. 2017 Oct;14(10):e275-e444. doi: 10.1016/j.hrthm.2017.05.012. Epub 2017 May 12.
7
Are Some Anticoagulants More Equal Than Others? - Evaluating the Role of Novel Oral Anticoagulants in AF Ablation.某些抗凝剂是否比其他的更具优势？——评估新型口服抗凝剂在房颤消融中的作用
Curr Cardiol Rev. 2016;12(4):330-335. doi: 10.2174/1573403x12666160505113755.
8
Network meta-analysis of efficacy and safety of competitive oral anticoagulants in patients undergoing radiofrequency catheter ablation of atrial fibrillation.竞争性口服抗凝剂在心房颤动射频导管消融患者中疗效和安全性的网状荟萃分析。
J Interv Card Electrophysiol. 2016 Sep;46(3):213-24. doi: 10.1007/s10840-016-0126-5. Epub 2016 Mar 21.
9
Efficacy and safety of rivaroxaban compared with vitamin K antagonists for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis.利伐沙班与维生素K拮抗剂用于心房颤动导管消融围手术期抗凝的疗效和安全性：一项系统评价和荟萃分析。
Europace. 2016 Dec;18(12):1787-1794. doi: 10.1093/europace/euv408. Epub 2016 Jan 20.
10
2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society.2012年心房颤动导管消融与外科消融专家共识声明：患者选择、手术技术、患者管理与随访、定义、终点及研究试验设计的建议：心律学会（HRS）心房颤动导管消融与外科消融特别工作组报告。与欧洲心脏病学会（ESC）注册分支欧洲心律协会（EHRA）及欧洲心脏心律失常学会（ECAS）合作制定；并与美国心脏病学会（ACC）、美国心脏协会（AHA）、亚太心律学会（APHRS）和胸外科医师学会（STS）协作。得到美国心脏病学会基金会、美国心脏协会、欧洲心脏心律失常学会、欧洲心律协会、胸外科医师学会、亚太心律学会和心律学会管理机构的认可。
Heart Rhythm. 2012 Apr;9(4):632-696.e21. doi: 10.1016/j.hrthm.2011.12.016. Epub 2012 Mar 1.